Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time
Keywords:
COVID-19 vaccines, safety, adverse drug reactions, epidemiology, public health
Abstract
Objective: The aim of this review is to describe the regulatory background of the COVID-19 vaccines, the national recommendations for use issued and vaccine uptake in Sweden. It includes an overview of licensing and relevant safety aspects identified by the European Medicines Agency (EMA) and the national vaccination plan issued by the Public Health Agency (PHA) of Sweden.
Materials and methods: Information on dates of licensing and safety aspects of importance identified by EMA published on its website, was compiled and presented in a chronological order. National recommendations on COVID-19-vaccination and vaccinations-data on uptake and coverage using the national-vaccine-register are presented.
Results: COVID-19 vaccines development, assessments using rolling review and licensing of the covid-19 vaccines was done in 2020 during less than a year. Large-scale production was implemented. Monthly safety reviews performed by the EMA identified risk for thrombosis with thrombocytopenia syndrome with adenoviral vaccines and myocarditis for mRNA vaccines which led to restrictions in national recommendations for specified groups.
National vaccinations were launched in a phased manner during 2021. Persons of high age, risk groups and nursing home personnel were prioritised during primary vaccinations and for initial boosters. In the Swedish population, 85% recieved at least on vaccine dose from the age of 12. At least two doses were recieved by 81% from age 18 and 95% from age 80.
Conclusion: Recommendations for national use adhered to relevant adverse drug reactions identified. The vaccine coverage was high. Timelines presented should be considered in follow-up studies of COVID-19-vaccines to manage possible selection bias and confounding.
Downloads
Download data is not yet available.
References
1. Kalinke U, Barouch DH, Rizzi R, Lagkadinou E, Türeci Ö, Pather S, et al. Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022;21(5):609–19. doi: 10.1080/14760584.2022.2042257
2. Human regulatory: overview. European Medicines Agency (EMA) (europa.eu). Available from: https://www.ema.europa.eu/en/human-regulatory-overview [cited 20 June 2025].
3. Authorisation of medicines. European Medicines Agency (EMA) (europa.eu). Available from: https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines [cited 20 June 2025].
4. European medicines regulatory network. European Medicines Agency (EMA) (europa.eu). Available from: https://www.ema.europa.eu/en/about-us/how-we-work/european-medicines-regulatory-network [cited 20 June 2025].
5. Pharmacovigilance Risk Assessment Committee (PRAC). European Medicines Agency (EMA) (europa.eu). Available from: https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac [cited 20 June 2025].
6. Rekommendationer för vaccination mot covid-19 – Folkhälsomyndigheten. Available from: https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/rekommendationer-for-vaccination/rekommendationer-om-vaccination-mot-covid-19/ [cited 20 June 2025].
7. Ludvigsson JF, Bergman D, Lundgren CI, Sundquist K, Geijerstam JA, Glenngård AH, et al. The healthcare system in Sweden. European Journal of Epidemiology 2025;40:563–579. doi: 10.1007/s10654-025-01226-9
8. Statistik för vaccination mot covid-19 – Folkhälsomyndigheten (folkhalsomyndigheten.se). Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-visualisering/vaccinationsstatistik/statistik-for-vaccination-mot-covid-19/ [cited 2 June 2025].
9. SARS-CoV-2 variants of concern as of 20 December 2024. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern [cited 20 June 2025].
10. Ljung R, Sundström A, Grünewald M, Backman C, Feltelius N, Gedeborg R, et al. The profile of the Covid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Upsala Journal of Medical Sciences 2021;126:e8136. doi: 10.48101/ujms.v126.8136
11. Cameron-Blake E, Tatlow H, Andretti B, Boby T, Green K, Hale T, et al. A panel dataset of COVID-19 vaccination policies in 185 countries. Nat Hum Behav. 2023;7(8):1402–13. doi: 10.1038/s41562-023-01615-8
12. COVID-19 Vaccines Advice. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice [cited 20 June 2025].
13. Xie W, Shi L, Liu M, Yang J, Ma M, Sun G. Disparities and effectiveness of COVID-19 vaccine policies in three representative European countries. International Journal for Equity in Health 2024;23:16. doi: 10.1186/s12939-024-02110-w
14. Li Y, Li M, Rice M, Su Y, Yang C. Phased implementation of COVID-19 vaccination: rapid assessment of policy adoption, reach and effectiveness to protect the most vulnerable in the US. Int. J. Environ. Res. Public Health 2021;18:7665.
15. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. 2023;382:e075286. doi: 10.1136/bmj-2022-075286
16. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ. 2023;382:e074325. doi: 10.1136/bmj-2022-074325
17. Bert F, Scaioli G, Vola L, Accortanzo D, Lo Moro G, Siliquini R. Booster doses of anti COVID-19 vaccines: An overview of implementation policies among OECD and EU countries. Int J Environ Res Public Health. 2022;19(12): 7233. doi: 10.3390/ijerph19127233
18. Guideline on good pharmacovigilance practices (GVP). Module V – Risk management systems (Rev 2). Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf [cited 20 June 2025].
19. Vaxzevria (previously COVID-19 Vaccine AstraZeneca) – direct healthcare professional communication (DHPC). European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca [cited 20 June 2025].
20. Jcovden (previously COVID-19 Vaccine Janssen) – direct healthcare professional communication (DHPC). European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/medicines/dhpc/jcovden-previously-covid-19-vaccine-janssen [cited 20 June 2025].
21. Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis. European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis [cited 20 June 2025].
22. COVID-19 mRNA Vaccines Comirnaty and Spikevax. Available from: https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-covid-19-mrna-vaccines-comirnaty-and-spikevax-risk-myocarditis-and-pericarditis_en.pdf [cited 20 June 2025].
23. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 Vaccination and myocarditis in a Nordic cohort study of 23 Million residents. JAMA Cardiol. 2022;7(6):600–12. doi: 10.1001/jamacardio.2022.0583
24. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November – 2 December 2021. European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021 [cited 20 June 2025].
25. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320. Update in: BMJ. 2022;377:o1205. doi: 10.1136/bmj.o1205
26. Norman M, Navér L, Söderling J, Ahlberg M, Hervius Askling H, Aronsson B, et al. Association of maternal SARS-CoV-2 infection in pregnancy with neonatal outcomes. JAMA. 2021;325(20):2076–86. doi: 10.1001/jama.2021.5775
27. COVID-19 Vaccines Safety Update February 2022 COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy. European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/news/covid-19-latest-safety-data-provide-reassurance-about-use-mrna-vaccines-during-pregnancy [cited 20 June 2025].
28. Comirnaty, INN-raxtozinameran, bretovameran, mRNA encoding KP.2. Available from: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf [cited 20 June 2025].
29. Lag om ändring av lagen (2012:453) om register över nationella vaccinationsprogram. Svensk författningssamling. Available from: https://svenskforfattningssamling.se/doc/20201194.html [cited 20 June 2025].
30. European Centre for Disease Prevention and Control (ECDC). Vaccine tracker. Available from: https://vaccinetracker.ecdc.europa.eu/public/extensions/covid-19/vaccine-tracker.html [cited 18 June 2025].
31. Fortsatt stor vilja att vaccinera sig mot covid-19 – Folkhälsomyndigheten (archive.org). Available from: https://web.archive.org/web/20210607184754/https:/www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2021/maj/fortsatt-stor-vilja-att-vaccinera-sig-mot-covid-19/ [cited 20 June 2025].
32. Reilev M, Olesen M, Kildegaard H, Støvring H, Andersen JH, Hallas J, et al. Changing characteristics over time of individuals receiving COVID-19 vaccines in Denmark: a population-based descriptive study of vaccine uptake. Scand J Public Health. 2022;50(6):686–92. doi: 10.1177/14034948221108246
33. Health Emergency Preparedness and Response (HERA) – European Commission. Available from: https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera_en [cited 20 June 2025].
34. WHO Pandemic Agreement. Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA78/A78_R1-en.pdf [cited 20 June 2025].
35. Ludvigsson JF, Håberg SE, Knudsen GP, Lafolie P, Zoega H, Sarkkola C, et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol. 2015;7:491–508. doi: 10.2147/CLEP.S90589
2. Human regulatory: overview. European Medicines Agency (EMA) (europa.eu). Available from: https://www.ema.europa.eu/en/human-regulatory-overview [cited 20 June 2025].
3. Authorisation of medicines. European Medicines Agency (EMA) (europa.eu). Available from: https://www.ema.europa.eu/en/about-us/what-we-do/authorisation-medicines [cited 20 June 2025].
4. European medicines regulatory network. European Medicines Agency (EMA) (europa.eu). Available from: https://www.ema.europa.eu/en/about-us/how-we-work/european-medicines-regulatory-network [cited 20 June 2025].
5. Pharmacovigilance Risk Assessment Committee (PRAC). European Medicines Agency (EMA) (europa.eu). Available from: https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac [cited 20 June 2025].
6. Rekommendationer för vaccination mot covid-19 – Folkhälsomyndigheten. Available from: https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/rekommendationer-for-vaccination/rekommendationer-om-vaccination-mot-covid-19/ [cited 20 June 2025].
7. Ludvigsson JF, Bergman D, Lundgren CI, Sundquist K, Geijerstam JA, Glenngård AH, et al. The healthcare system in Sweden. European Journal of Epidemiology 2025;40:563–579. doi: 10.1007/s10654-025-01226-9
8. Statistik för vaccination mot covid-19 – Folkhälsomyndigheten (folkhalsomyndigheten.se). Available from: https://www.folkhalsomyndigheten.se/folkhalsorapportering-statistik/statistikdatabaser-och-visualisering/vaccinationsstatistik/statistik-for-vaccination-mot-covid-19/ [cited 2 June 2025].
9. SARS-CoV-2 variants of concern as of 20 December 2024. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern [cited 20 June 2025].
10. Ljung R, Sundström A, Grünewald M, Backman C, Feltelius N, Gedeborg R, et al. The profile of the Covid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Upsala Journal of Medical Sciences 2021;126:e8136. doi: 10.48101/ujms.v126.8136
11. Cameron-Blake E, Tatlow H, Andretti B, Boby T, Green K, Hale T, et al. A panel dataset of COVID-19 vaccination policies in 185 countries. Nat Hum Behav. 2023;7(8):1402–13. doi: 10.1038/s41562-023-01615-8
12. COVID-19 Vaccines Advice. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice [cited 20 June 2025].
13. Xie W, Shi L, Liu M, Yang J, Ma M, Sun G. Disparities and effectiveness of COVID-19 vaccine policies in three representative European countries. International Journal for Equity in Health 2024;23:16. doi: 10.1186/s12939-024-02110-w
14. Li Y, Li M, Rice M, Su Y, Yang C. Phased implementation of COVID-19 vaccination: rapid assessment of policy adoption, reach and effectiveness to protect the most vulnerable in the US. Int. J. Environ. Res. Public Health 2021;18:7665.
15. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. 2023;382:e075286. doi: 10.1136/bmj-2022-075286
16. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ. 2023;382:e074325. doi: 10.1136/bmj-2022-074325
17. Bert F, Scaioli G, Vola L, Accortanzo D, Lo Moro G, Siliquini R. Booster doses of anti COVID-19 vaccines: An overview of implementation policies among OECD and EU countries. Int J Environ Res Public Health. 2022;19(12): 7233. doi: 10.3390/ijerph19127233
18. Guideline on good pharmacovigilance practices (GVP). Module V – Risk management systems (Rev 2). Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf [cited 20 June 2025].
19. Vaxzevria (previously COVID-19 Vaccine AstraZeneca) – direct healthcare professional communication (DHPC). European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/medicines/dhpc/vaxzevria-previously-covid-19-vaccine-astrazeneca [cited 20 June 2025].
20. Jcovden (previously COVID-19 Vaccine Janssen) – direct healthcare professional communication (DHPC). European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/medicines/dhpc/jcovden-previously-covid-19-vaccine-janssen [cited 20 June 2025].
21. Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis. European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis [cited 20 June 2025].
22. COVID-19 mRNA Vaccines Comirnaty and Spikevax. Available from: https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-covid-19-mrna-vaccines-comirnaty-and-spikevax-risk-myocarditis-and-pericarditis_en.pdf [cited 20 June 2025].
23. Karlstad Ø, Hovi P, Husby A, Härkänen T, Selmer RM, Pihlström N, et al. SARS-CoV-2 Vaccination and myocarditis in a Nordic cohort study of 23 Million residents. JAMA Cardiol. 2022;7(6):600–12. doi: 10.1001/jamacardio.2022.0583
24. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November – 2 December 2021. European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-29-november-2-december-2021 [cited 20 June 2025].
25. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320. Update in: BMJ. 2022;377:o1205. doi: 10.1136/bmj.o1205
26. Norman M, Navér L, Söderling J, Ahlberg M, Hervius Askling H, Aronsson B, et al. Association of maternal SARS-CoV-2 infection in pregnancy with neonatal outcomes. JAMA. 2021;325(20):2076–86. doi: 10.1001/jama.2021.5775
27. COVID-19 Vaccines Safety Update February 2022 COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy. European Medicines Agency (EMA). Available from: https://www.ema.europa.eu/en/news/covid-19-latest-safety-data-provide-reassurance-about-use-mrna-vaccines-during-pregnancy [cited 20 June 2025].
28. Comirnaty, INN-raxtozinameran, bretovameran, mRNA encoding KP.2. Available from: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf [cited 20 June 2025].
29. Lag om ändring av lagen (2012:453) om register över nationella vaccinationsprogram. Svensk författningssamling. Available from: https://svenskforfattningssamling.se/doc/20201194.html [cited 20 June 2025].
30. European Centre for Disease Prevention and Control (ECDC). Vaccine tracker. Available from: https://vaccinetracker.ecdc.europa.eu/public/extensions/covid-19/vaccine-tracker.html [cited 18 June 2025].
31. Fortsatt stor vilja att vaccinera sig mot covid-19 – Folkhälsomyndigheten (archive.org). Available from: https://web.archive.org/web/20210607184754/https:/www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2021/maj/fortsatt-stor-vilja-att-vaccinera-sig-mot-covid-19/ [cited 20 June 2025].
32. Reilev M, Olesen M, Kildegaard H, Støvring H, Andersen JH, Hallas J, et al. Changing characteristics over time of individuals receiving COVID-19 vaccines in Denmark: a population-based descriptive study of vaccine uptake. Scand J Public Health. 2022;50(6):686–92. doi: 10.1177/14034948221108246
33. Health Emergency Preparedness and Response (HERA) – European Commission. Available from: https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera_en [cited 20 June 2025].
34. WHO Pandemic Agreement. Available from: https://apps.who.int/gb/ebwha/pdf_files/WHA78/A78_R1-en.pdf [cited 20 June 2025].
35. Ludvigsson JF, Håberg SE, Knudsen GP, Lafolie P, Zoega H, Sarkkola C, et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol. 2015;7:491–508. doi: 10.2147/CLEP.S90589
Published
2025-10-16
How to Cite
Zethelius , B., Rubin , J., Pihlström , N., Wändel Liminga , U., Back , H., Aronsson , B., Tegnell , A., Marking , U., Ludvigsson , J. F., Andersson , S., & Ljung , R. (2025). Overview of approved COVID-19 vaccines in the EU, recommendations for use in Sweden and vaccine uptake over time. Upsala Journal of Medical Sciences, 130, e12937. https://doi.org/10.48101/ujms.v130.12937
Section
Original Articles
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Upsala Medical Society. Read the full Copyright- and Licensing Statement.
